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NMR studies of group 8 metallodrugs:
187Os-enriched organo-osmium half-sandwich
anticancer complex†
Russell J. Needham, Ivan Prokes, Abraha Habtemariam,
Isolda Romero-Canelón, ‡ Guy J. Clarkson and Peter J. Sadler *
We report the synthesis of the organo-osmium anticancer complex [Os(η6-p-cym)(N,N-azpy-NMe2)Br]
PF6 (1) containing natural abundance
187Os (1.96%), and isotopically-enriched (98%) [187Os]-1. Complex
1 and [187Os]-1 contain a π-bonded para-cymene (p-cym), a chelated 4-(2-pyridylazo)-N,N-dimethyl-
aniline (azpy-NMe2), and a monodentate bromide as ligands. The X-ray crystal structure of 1 confirmed
its half-sandwich ‘piano-stool’ configuration. Complex 1 is a member of a family of potent anticancer
complexes, and exhibits sub-micromolar activity against A2780 human ovarian cancer cells (IC50 =
0.40 µM). Complex [187Os]-1 was analysed by high-resolution ESI-MS, 1D 1H and 13C NMR, and 2D 1H
COSY, 13C–1H HMQC, and 1H–187Os HMBC NMR spectroscopy. Couplings of 1H and 13C nuclei from
the azpy/p-cym ligands to 187Os were observed with J-couplings (1J to 4J) ranging between 0.6–8.0
Hz. The 187Os chemical shift of [187Os]-1 (−4671.3 ppm, determined by 2D 1H–187Os HMBC NMR) is
discussed in relation to the range of values reported for related Os(II) arene and cyclopentadienyl com-
plexes (−2000 to −5200 ppm).
Introduction
There is much current interest in the design of transition
metal anticancer complexes.1–4 Progress depends on the eluci-
dation of structure–activity relationships and their mecha-
nisms of action, depends on the identification of their phar-
macophores, the active species. Although some metal com-
plexes are relatively inert (e.g. low-spin d6 complexes), many
are pro-drugs which will undergo ligand exchange and redox
reactions before reaching the target site. NMR is a potentially
powerful method for investigating metallodrug speciation,
since studies can be carried out in solution under physiologi-
cally relevant conditions, and information on the thermo-
dynamics (equilibria) and kinetics (dynamics) of ligand
exchange reactions can often be obtained. Direct observation
of NMR resonances for the metals themselves (heteronuclear
NMR) is potentially very informative, but often difficult to
achieve.
We focus here on group 8 transition metals, Fe, Ru and Os.
In particular two Ru(III) complexes, NAMI-A ([trans-
RuCl4(DMSO-S)(Im)]ImH, where Im = imidazole) and KP1019
([trans-RuCl4(In)2]InH, where In = indazole) have been on clini-
cal trials.5 Ru(III) complexes are paramagnetic, but diamagnetic
low-spin 4d6 Ru(II) complexes, can in principle, be studied by
99Ru and 101Ru NMR, Table 1. Their natural abundances are
reasonable (12.76% and 17.06%, respectively), and although
their gyromagnetic ratios are relatively low, they should be
detectable with similar sensitivities as 13C. However, both are
quadrupolar with I = 52;
101Ru has a higher quadrupole
moment than 99Ru. Both isotopes give rise to broad lines
unless in highly symmetrical complexes. The complexes [Ru
(NH3)6]Cl2 and K4[Ru(CN)6] (notably with a temperature coeffi-
cient for the chemical shift of >1 ppm K−1) give narrow reso-
nances and are useful references.6 99Ru solution studies on
such symmetrical complexes are also possible.7 For tris-(poly-
pyridyl)Ru(II) complexes in acetonitrile, a correlation between
the 99Ru-NMR chemical shifts and the energy of metal-to-
ligand charge transfer has been reported.8 The chemical shift
range for 99Ru is >9000 ppm. The 99Ru NMR linewidth of 0.15
M [RuII(bipyridine)3]PF6 in CD3CN is 65 Hz, and for other
polypyridyl complexes up to 800 Hz, depending on the
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counter-anion and concentration.9 There is medical interest in
related complexes as photodynamic agents for the treatment
of cancer. TLD-1433, [Ru(4,4′-dimethyl-2,2′-bipyridine)2(2-
(2′,2″:5″,2′′′-terthiophene)-imidazo[4,5-f ][1,10]phenanthroline)]
Cl2, an octahedral tris-diimine Ru(II) complex with two methyl-
ated bipyridyl and one phenanthroline derivative as ligands, is
activated by green light and currently on clinical trial for treat-
ment of non-muscle invasive bladder cancer (NMIBC), which
is refractory to Bacillus Calmette–Guérin (BCG) treatment.10,11
Complexes of lower symmetry, such as half-sandwich Ru(II)
arene anticancer complexes give resonances which are usually
too broad to observe easily (unpublished data).
Although both Ru(II) and Ru(III) complexes have been widely
explored as anticancer agents, similar studies of osmium com-
plexes are more recent.13–15 Os(VI) complexes, of general
formula [Os{N}(N^N)Cl3] (where N^N = 2,2′-bipyridine or a
phenanthroline derivative), can attack DNA and induce endo-
plasmic reticulum stress, probably through protein
binding.16,17 Half sandwich diamine Os(II) arene anticancer
complexes can also bind to DNA and inhibit DNA
synthesis,18–20 whereas azopyridine complexes are more inert
and have a redox mechanism of action. Particularly potent is
the iodido complex [Os(η6-p-cym)(N,N-azpy-NMe2)I]PF6 (FY26;
p-cym = para-cymene, azpy-NMe2 = 2-(p-((dimethylamino)phe-
nylazo)pyridine), which is ca. 49× more active on average than
the anticancer drug cisplatin towards a Sanger Institute panel
of over 800 cancer cell lines, and induces formation of reactive
oxygen species (ROS) in cancer cells.21,22 This complex is
capable of delaying the growth of HCT-116 human colon
cancer xenografts in mice,23 and is up to 64× more selective
towards A2780 ovarian cancer cells over normal cells when
applied synergistically with L-buthionine sulfoximine, which
blocks glutathione (γ-L-Glu-L-Cys-Gly, GSH) synthesis.24 The
complex FY26 is inert to hydrolysis, but undergoes activation
in cancer cells by attack on the azo bond by the intracellular
thiol GSH, resulting in liberation of the iodido ligand.25
Table 1 Properties of isotopes of group 8 transition metals which possess a nuclear spin12
Metal Isotope Abundance (%) Nuclear spin (I) Quadrupole momenta Frequencyb Receptivityc (Rel. to 13C)
Iron 57Fe 2.119 1/2 — 12.955 4.25 × 10−3
Ruthenium 99Ru 12.76 5/2 7.9 16.427 0.85
101Ru 17.06 5/2 45.7 12.750 1.58
Osmium 187Os 1.96 1/2 — 9.132 1.43 × 10−3
189Os 16.15 3/2 85.6 31.072 2.32
a Electric quadrupole moment in units of fm2 (10−30 m2; 1 barn = 100 fm2). b 1H 400 MHz, 13C 100 MHz. c Receptivity at natural abundance rela-
tive to 13C.
Scheme 1 The multi-step synthesis of [187Os(η6-p-cym)(N,N-azpy-NMe2)Br]PF6 with 187Os isotopic enrichment, starting from 187Os metal powder.
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Additional current interest in organo-osmium(II) half sand-
wich complexes arises from their activity as transfer hydrogen-
ation catalysts. For example, chiral arene (p-toluenesulfonyl)-
1,2-diphenylethylenediamine (TsDPEN) complexes, [Os(arene)
(TsDPEN)], are effective catalysts for the conversion of the
natural metabolite pyruvate into either natural L-lactate or un-
natural D-lactate depending on the enantiomer of the catalyst
used, reactions of which can be achieved even inside cancer
cells.26,27
Osmium NMR studies are highly challenging, firstly, the
natural abundance in the Earth’s crust is very low, ca. 1 g
per 200 tonnes, making it amongst the rarest stable
elements in the periodic table.28 There are seven stable
naturally-occurring osmium isotopes:29 184Os (0.02%), 186Os
(1.59%), 187Os (1.96%), 188Os (13.24%), 189Os (16.15%),
190Os (26.26%), 192Os (40.78%), one of which (186Os) is a
radioisotope with a half-life of 2.011 × 1015 years (α-decay),
and for practical purposes is considered ‘stable’. Of the




2, respectively), making them both magnetically recep-
tive.30 189Os has a high quadrupole moment (Q = 0.91) and
low gyromagnetic ratio (Table 1), making it relatively insen-
sitive to detection (1.43 × 10−3 at natural abundance relative
to 13C), due to quadrupolar relaxation. 189Os is therefore
unsuitable for most NMR studies, with the exception of
highly symmetrical molecules like 189OsO4, which yields a
broad signal.
187Os is a radioactive decay product of 187Re (half-life of
4.56 × 1010 years) and has been studied extensively in the
dating of terrestrial and meteoric rocks, and hydrocarbon
deposits.31 It is an I = 12 nucleus capable of yielding sharp NMR
peaks over a chemical shift range of >5000 ppm. Bell et al.
demonstrated that the use of polarisation transfer techniques
to observe J (187Os–1H/31P) couplings can greatly enhance the
Fig. 1 ORTEP diagram for the cation in the X-ray crystal structure of
[Os(η6-p-cym)(azpy-NMe2)Br]PF6. Ellipsoids are shown at the 50% prob-
ability level and all hydrogens, counter ions and solvent molecules have
been omitted for clarity.
Fig. 2 Observed and calculated positive-ion high resolution mass spectra of (A) natural abundance complex 1 ([M − PF6]+; [C23H28N4BrOs]+), and
(B) 187Os-enriched [187Os]-1 ([M − PF6]+; [C23H28N4Br187Os]+). The simplification of the spectrum on enrichment due to the presence of predomi-
nantly only one osmium isotope (187Os) together with 79Br (51%) and 81Br (49%) is apparent.
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sensitivity of 187Os detection, with maximum gains of 1300
and 12 000 for 31P and 1H-detected spectra.32 This polarisation
transfer approach had been applied also to µ-hydrido and Cp
complexes.32–34 Bell et al. utilised one-bond 187Os–1H (hydride)
couplings of ca. 70 Hz, and 187Os–31P couplings to phosphines
of ca. 270 Hz, to detect 187Os NMR peaks for 37 [Os(arene)
X2(PR3)] complexes. In a previous study on the biphenyl sand-
wich complex [Os(η6-bip)2](OTf)2, we used 1H/187Os heteronuc-
lear multiple bond correlation (HMBC) spectroscopy to
observe the 187Os resonance for a 25 mM solution of the
complex via the small 187Os–1H couplings to arene ring
protons.35
Here we have synthesised the bromido analogue of the
iodido complex FY26, [Os(η6-p-cym)(N,N-azpy-NMe2)Br]PF6 (1),
and determined its X-ray crystal structure. Also we have syn-
thesised on a milligram scale, the 187Os isotopically-enriched
complex [187Os]-1, carried out multinuclear NMR and MS
studies, and determined the antiproliferative activity of 1
towards human cancer cells. This appears to be the first report
of NMR studies on a 187Os-enriched complex.
Results and discussion
Synthesis and characterisation
The synthesis of the 187Os isotopically-enriched complex,
[187Os(η6-p-cym)(N,N-azpy-NMe2)Br]PF6 ([187Os]-1), from ca.
50 mg metallic osmium-187 (98% enriched) was achieved in
five steps based on previously reported methods (Scheme 1),
with an overall yield of 41%.36,37 The non-enriched complex 1
was synthesised from K2[OsO2(OH)4], also via reported
methods, and is analogous to the highly active complex [Os(η6-
p-cym)(N,N-azpy-NMe2)I]PF6 (FY26),
21 with bromide replacing
iodide as the monodentate ligand.
The X-ray crystal structure of complex 1 shows that it adopts
a similar pseudo-octahedral three-legged piano-stool geometry
to its analogue, FY26, (Fig. 1, Table S1†).25 Osmium(II) is
π-bonded to a p-cym ligand, and coordinated to a monoden-
tate bromide and a bidentate azopyridine ligand, which consti-
tute the three legs of the piano-stool. The complex crystallises
as a racemate owing to the chiral Os centre, and contains a
PF6
− counter-anion.
Fig. 3 700 MHz 1H NMR spectrum of [187Os]-1 (LHS), and 400 MHz 2D 1H COSY NMR spectrum of 1 with all 1H resonances assigned. (A) The aro-
matic region, and (B) the aliphatic region. Samples were prepared in MeCN-d3.
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Similarly to FY26, complex 1 exhibits potent sub-micromolar
antiproliferative activity against A2780 human ovarian cancer
cells (IC50 = 0.40 ± 0.01 µM, 24 h drug exposure, 72 h recovery)
and probably has a similar mechanism of action, inducing for-
mation of reactive oxygen species (ROS) and perturbing the
redox balance in cancer cells. The IC50 follows an expected
trend of activity for change in the monodentate ligand: I > Br >
Cl, whereby the iodido complex is the most active and the
chlorido complex is the least, due to weakening of the Os–X
bond decreasing stability, and hence greater drug deactivation
before reaching the target sites (Table S2†). This trend was
observed previously for a related bromido Os(II) arene azopyri-
dine complex and its halido analogues.38 The racemic nature
of the complex would be expected to have little effect on
activity, since previous studies on the separated enantiomers
of FY26 showed that the chiral centre does not significantly
change the anticancer activity.39
Mass spectrometry
The observed and calculated positive-ion high resolution mass
spectra of natural abundance complex 1 ([M − PF6]+;
[C23H28N4BrOs]
+) and [187Os]-1 ([M − PF6]+; [C23H28N4Br187Os]+)
are compared in Fig. 2A and B, respectively. The spectrum of
enriched [187Os]-1 is greatly simplified due to the presence of
predominantly only one osmium isotope (187Os) instead of 4
Fig. 4 1H NMR (250 MHz) spectra of [187Os]-1 compared to natural abundance 1, with expansions of the resonances for 1Ha,
1Hb, and
1Hd illustrating
their couplings to other protons and 187Os. Samples were prepared in MeCN-d3.
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additional isotopes (188Os 13.24%, 189Os 16.15%, 190Os 26.26%,
and 192Os 40.78%). The presence of 79Br (natural abundance
51%) and 81Br (49%) isotopes is apparent.
1H NMR
Complexes 1 and [187Os]-1 were prepared in MeCN-d3
(∼10 mg mL−1) and 1H COSY NMR spectra were recorded on
400 and 700 MHz instruments (Fig. 3), and the resonances
assigned. To resolve coupling interactions between 187Os and
1H nuclei, 250 MHz 1H NMR spectra of the samples were also
recorded (Fig. 4). As expected, no 187Os–1H coupling inter-
actions were observed for 1 due to the low natural abundance
of 187Os (1.96%). However, the 1H spectrum of [187Os]-1 shows
the presence of 3- and 4-bond couplings between 187Os and
1Ha (
3J = 1.7 Hz), and 1Hb (
4J = 0.6 Hz). There was also a small
unresolved coupling to 1Hd; the resolution was not sufficient
to measure 4J. The resonance for proton 1Hc is overlapped with
other resonances, although the 5J value might be expected to
be very small compared to the linewidth.
13C NMR
The samples used for 1H NMR studies were also analysed by
13C NMR, utilising a J-MOD sequence (Fig. 5). To aid character-
isation of the resonances, a 13C–1H HMQC NMR spectrum was
recorded (Fig. S1†), and all 23 13C resonances were observed
and characterised in the spectrum. Furthermore, expansions
of some resonances reveal distinct 187Os–13C couplings for





1J = 7.2–8.0 Hz), which
comprise the four CH carbons of the arene ring of the p-cym
ligand, and between 187Os and the two tertiary carbons of the
ring, 13Co and
13Cr (
1J = 4.7 and 5.9 Hz, respectively).
Furthermore, longer range couplings are observed between
187Os and 13Ce and
13Cf (
2J = 2.4 and 5.0 Hz, respectively), and
between 187Os and 13Cb (
3J = 1.8 Hz), which comprise 13C reso-
nances of the bidentate azpy ligand. Table 2 lists all the
observed 187Os–1H and 187Os–13C couplings.
1H–187Os HMBC
Utilising 1H–187Os HMBC, we were able to observe the 187Os
resonance of [187Os]-1 and determine its chemical shift relative
to OsO4. The resonance was observed at −4671.3 ppm through
correlation with aromatic proton Ha (pyridyl ring), and ali-
phatic protons from the arene ligand, Hn (Fig. 7). Attempts to
observe directly the 187Os resonance of [187Os]-1 were unsuc-
cessful (Fig. S2†). The very low gyromagnetic ratio of 187Os
makes direct observation difficult, despite the complex being
isotopically enriched. Fig. 8 shows a comparison of 187Os
chemical shifts for various organo-osmium complexes with
arene and cyclopentadienyl ligands. The comparatively low
chemical shift of the (high-field-shifted) 187Os resonance of
[187Os]-1, similar to a bis-biphenyl arene Os(II) sandwich
complex, suggests a highly shielded 187Os nucleus, perhaps
surprising on account of the presence of the strong π-acceptor
Fig. 5 176 Hz 13C NMR spectrum of [187Os]-1 using the J-MOD sequence, with 13C assignments. The sample was prepared in MeCN-d3. C and CH2
peaks are upright, CH and CH3 peaks inverted.
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azopyridine ligand, although the comparator complexes
mostly contain phosphines, or hydride ligands. Future work is
required to elucidate the relationship between the electron
densities in these complexes and the 187Os chemical shifts,
e.g. DFT calculations.
Heteronuclear NMR for metallodrugs
Most NMR spectroscopic studies of metallodrugs involve
nuclei which are the most sensitive to detection. Only a few
NMR nuclei offer the sensitivity for studies at pharmacological
concentrations. These include 1H, 19F, 31P, and 13C and 15N
with enrichment and detection by polarisation transfer
methods. Studies of NMR-active isotopes of metals present sig-
nificant challenges.41–43
Sensitivity is a function of the size of the gyromagnetic ratio
(γ, proportional to the frequency of detection of resonances),
the natural abundance, and the applied magnetic field (B0).
NMR signal intensity is proportional to B3=20 γ
5/2. In general, as
nuclei become heavier, they have smaller gyromagnetic ratios
and they become less sensitive to detection. The detection sen-
sitivity of low abundance nuclei such as 13C and 15N, which
are often coupled to more sensitive 1H nuclei, can be greatly
enhanced by use of spin-polarisation-transfer pulse sequences
such as heteronuclear single quantum coherence (HSQC), e.g.
for 15N by up to a factor of 306 (|γ1H|/|γ15N|)5/2.
All elements in the periodic table from atomic number 1
to 103 have at least one isotope which possesses nuclear
spin.29,44 Radioactivity can be a problem for some elements,
although shielding by glass is adequate for tritium (3H),
which has a higher gyromagnetic ratio than 1H and is 1.21×
more sensitive to detection. A more common problem is that
nuclei with spin quantum numbers >12 (quadrupolar nuclei)
in environments that are not symmetrical, usually suffer line
broadening via interaction with electric field gradients. For
nuclei with high quadrupole moments (e.g. 197Au), this can
lead to extreme broadening making resonances very difficult,
and sometimes almost impossible to detect. Line broadening
can also be severe for paramagnetic metal complexes,
especially complexes where the unpaired spins have long
electron spin relaxation times (those detectable by EPR at








13Ct, which all exhibit couplings to
187Os. Samples were prepared in MeCN-d3.
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ambient temperature), and when there are exchange pro-
cesses which occur at intermediate rates on the NMR time-
scale. The resonances of heavier nuclei can be broadened by
chemical shift anisotropy relaxation mechanisms (e.g. 195Pt
in square-planar complexes), which also broadens 195Pt satel-
lites in 1H NMR spectra of Pt(II) ligands. Such broadening is
proportional to B20 so can make such satellites very broad at
high frequencies (e.g. at 600 MHz versus 300 MHz).45
There is also current pharmacological interest in the
group 8 metal iron. Ferrocene in particular shows promise as
a fragment for conjugation in drug design.46,47 Ferroquine is
on clinical trial as an antimalarial drug,48 and ferrocifens
(tamoxifen derivatives) have promising anticancer activity
especially towards breast cancer cells possessing the estrogen
receptor (ER+).49 57Fe is an I = 12 nucleus, but the abundance
is low (2.1%), as is the gyromagnetic ratio, Table 1. With
polarisation transfer from 1H, utilising the small two-bond
Cp (C–H) 1H–57Fe coupling of ca. 0.5 Hz, 57Fe resonances can
readily be detected for concentrated solutions of ferrocene
(ca. 0.4 M).50 57Fe chemical shifts have been used to study
the donor properties of amino groups on coordinated Cp
rings.51 57Fe isotopic enrichment (to ca. 90%) allows detec-
tion at millimolar concentrations, e.g. for haem proteins.52
Enrichment combined with polarisation-transfer methods
should allow detection at pharmacological concentrations of
relevance to metallodrug activity. However, oxidation to para-
magnetic 3d5 Fe(III) is likely to lead to severe broadening and
loss of 57Fe resonances.
Fig. 7 2D 1H–187Os HMBC NMR spectrum of [187Os]-1 in MeCN-d3.



















a The signs of the coupling constants have not been determined.
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NMR is a versatile technique for the study of metallodrugs in
both the solid state and solution. Here we have focussed on
solution studies, which can not only provide structural infor-
mation, but also insights into both the thermodynamics and kine-
tics of ligand exchange reactions. Such information is vital for
identifying pharmacologically active species. The common spin-12
nuclei 1H, 19F and 31P are sensitive enough for NMR studies at
physiologically relevant concentrations (often sub-millimolar),
and so too are 13C and 15N in isotopically-enriched compounds,
especially when polarisation transfer methods such as HSQC are
used. In contrast, I > 12 (quadrupolar) nuclei usually give rise to
broad peaks which limits their usefulness at low concentrations.
Platinum anticancer drugs are now the most widely used
drugs in cancer chemotherapy, and NMR studies of the 33.4%
abundant I = 12 isotope
195Pt have proved useful for studies of
the activation of cisplatin and related drugs by hydrolysis and
subsequent attack of DNA target sites, as well as the reduction
of Pt(IV) prodrugs to Pt(II).4,41,43,53 Currently, there is much
interest in the discovery of active anticancer complexes of
other transition metals, and we have highlighted here the
potential for group 8 of the periodic table, iron, ruthenium,
and osmium. Complexes of ruthenium have already entered
clinical trials,54 and one is in clinical trials as a photosensiti-
zer for cancer treatment.10 However, ruthenium has only quad-
rupolar nuclei and direct studies of these drugs by Ru NMR
are difficult. The heavier congener, osmium, on the other
hand has a useful I = 12 isotope
187Os, although with a low
natural abundance and low gyromagnetic ratio (Table 1).
We have shown here that isotopic enrichment of a potent
anticancer complex [187Os(η6-p-cym)(N,N-azpy-NMe2)Br]PF6 to
>98% 187Os allows facile detection of its 187Os resonance NMR
using 2D 1H–187Os HMBC, and accompanying 1H and 13C
NMR studies allow detection for the first time of 1J, 2J, 3J and
4J coupling constants for both the arene ring and the chelated
azopyridine ligand, ranging from 0.6–8 Hz. However, despite
isotopic enrichment, direct observation of the 187Os resonance
(without the use of spin-polarisation-transfer techniques) was
not achievable due to its very low gyromagnetic ratio. The syn-
thesis of the enriched complex was achieved in good yield over
5 steps from metallic 187Os, the first step of which involved
conversion to 187OsO4, a highly toxic volatile compound gener-
ated in a KOH/KNO3 melt at >350 °C. The mechanism of anti-
cancer activity of this class of organo-osmium arene anticancer
complexes appears to be different from that of platinum anti-
cancer drugs, and further studies using such 187Os-enriched
complexes are likely to provide new insight into their reactions
in biological media and the nature of their target sites.
Experimental
Materials
Chemicals. 187Os powder was the kind gift of Dr Dimitrios
Bessas (ESRF, Grenoble). K2[OsO2(OH)4] and N,N-dimethyl-4-
Fig. 8 Comparison of 187Os chemical shifts for [187Os]-1 in comparison with values for arene and cyclopentadienyl Os(II) complexes in the
literature.33–35,40 Shifts are either referenced directly to OsO4 or indirectly from the proton frequency of TMS.
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(2-pyridylazo)aniline were purchased from Alfa Aesar, and
α-terpinene and ammonium hexafluorophosphate were pur-
chased from Sigma-Aldrich. All other general reagents (KOH,
KNO3, and HBr), and organic solvents were purchased from
commercial suppliers and used as received. Deionised water
for synthesis was produced using a Millipore Elix 5 water puri-
fication system.
Cell culture. DMEM cell culture media, penicillin/streptomy-
cin mixture, foetal bovine serum, L-glutamine, and trypsin
were all purchased from PAA Laboratories GmbH. DMEM was
supplemented with foetal bovine serum (50 mL), penicillin/
streptomycin mixture (5 mL), and L-glutamine (5 mL). The
A2780 cell line was purchased from the European Collection of
Cell Cultures.
Synthesis
[187Os(η6-p-cym)Br2]2. Powdered osmium-187 (50.3 mg,
0.267 mmol), KOH (0.5 g) and KNO3 (0.3 g) were mixed in an
alumina crucible and heated to 350–400 °C, yielding a brown
melt. After cooling to ambient temperature the solids were dis-
solved in H2O (10 mL). EtOH (20 mL) was added and a pink-
purple precipitate formed. The solvents were removed by
decantation and the precipitate washed with EtOH : H2O (3 : 1,
v/v, 3 × 15 mL). The clean precipitate was mixed with EtOH
(10 mL), HBr (48%, v/v, 5 mL) and heated under reflux for
18 h. α-Terpinene (501 mg, 3.678 mmol) was added and the
mixture was refluxed for a further 18 h. The product was
extracted with CH2Cl2 (25 mL) and washed with H2O (3 ×
20 mL). The solution was concentrated to ∼3 mL under
reduced pressure and a brown precipitate formed, which was
placed in a freezer overnight (253 K). The precipitate was col-
lected via vacuum filtration and washed with EtOH (5 mL) and
Et2O (5 mL). Yield (53.1 mg, 41%). No analysis was conducted
at this stage to avoid loss of valuable 187Os. Note: Extreme care
must be taken with the handling of the OsO4 intermediate
(Scheme 1).
Natural abundance [Os(η6-p-cym)Br2]2 was synthesised from
K2[OsO2(OH)4] using a previously reported method.
37
[187Os(η6-p-cym)(N,N-azpy-NMe2)Br]PF6. [187Os(η6-p-cym)
Br2]2 (12.6 mg, 13.10 µmol) was dissolved in EtOH (10 mL),
and a solution of N,N-dimethyl-4-(2-pyridylazo)aniline (6.2 mg,
27.322 µmol) in EtOH (5 mL) was added drop-wise to the
stirred mixture. The mixture was stirred at 313 K for 2 h, then
NH4PF6 (21.2 mg, 0.130 mmol) was added. The mixture was
concentrated to ∼2 mL under reduced pressure and placed in
a freezer overnight (253 K). A dark blue precipitate formed,
which was collected via vacuum filtration and washed with ice-
cold EtOH (1 mL) and Et2O (5 mL). The product was dried in a
vacuum desiccator overnight. Yield: (18.6 mg, 92%). 1H NMR
250 MHz (CD3CN): δ 9.07 (dddd, 1H, J = 5.8, 1.6, 1.7, 1.0 Hz),
8.41 (m, 1H), 8.05–8.13 (m, 3H), 7.51 (dddd, 1H, J = 7.5, 5.9,
1.4, 0.6 Hz), 6.84–6.90 (m, 2H), 6.16–6.18 (m, 1H), 5.95–6.00
(m, 3H), 3.30 (s, 6H), 2.43 (s, 3H), 2.34 (sept., 1H, J = 6.9 Hz),
0.90 (d, 3H, J = 6.9 Hz), 0.85 (d, 3H, J = 6.9 Hz). 13C NMR
176 MHz (CD3CN): δ 167.75 (C), 156.56 (C), 154.21 (CH),
148.23 (C), 142.31 (CH), 130.33 (CH), 126.09 (CH), 124.41 (CH),
113.10 (CH), 103.36 (C), 102.02 (C), 83.03 (CH), 81.98 (CH),
80.87 (CH), 79.45 (CH), 40.83 (CH3), 32.08 (CH), 22.27
(CH3), 22.06 (CH3), 19.64 (CH3). ESI-MS calculated for
C23H28BrN4
187Os+: m/z 626.1049. Found: 626.1043.
Natural abundance [Os(η6-p-cym)(N,N-azpy-NMe2)Br]PF6
Synthesised using the same procedure as above with; [Os(η6-p-
cym)Br2]2 (58.6 mg, 60.548 μmol), N,N-dimethyl-4-(2-pyridy-
lazo)aniline (30.1 mg, 133.120 µmol), and NH4PF6 (98.6 mg,
0.605 mmol). Yield: (79.9 mg, 85%). 1H NMR 250 MHz
(CD3CN): δ 9.07 (ddd, 1H, J = 5.8, 1.4, 0.6 Hz), 8.41 (ddd, 1H, J
= 8.2, 1.3, 0.6 Hz), 8.05–8.13 (m, 3H), 7.51 (ddd, 1H, J = 7.5,
5.9, 1.4 Hz), 6.84–6.90 (m, 2H), 6.16–6.18 (m, 1H), 5.96–6.00
(m, 3H), 3.30 (s, 6H), 2.43 (s, 3H), 2.34 (sept., 1H, J = 6.9 Hz),
0.90 (d, 3H, J = 6.9 Hz), 0.85 (d, 3H, J = 6.9 Hz). 13C NMR
150 MHz (CD3CN): δ 167.75 (C), 156.56 (C), 154.20 (CH),
148.23 (C), 142.31 (CH), 130.33 (CH), 126.09 (CH), 124.41 (CH),
113.10 (CH), 103.36 (C), 102.01 (C), 83.02 (CH), 81.98 (CH),
80.86 (CH), 79.44 (CH), 40.83 (CH3), 32.08 (CH), 22.27 (CH3),
22.06 (CH3), 19.63 (CH3). ESI-MS calculated for
C23H28BrN4Os
+: m/z 631.1087. Found: 631.1091. CHN analysis:
Found: C, 35.37%; H, 3.44%; N, 7.37%. Calculated for
C23H28BrF6N4OsP: C, 35.62%; H, 3.64%; N, 7.22%.
X-ray crystal structure
A single crystal of complex 1 was grown by slow evaporation of
a methanolic solution (∼3 mg mL−1), and its molecular struc-
ture was determined by X-ray crystallography (Fig. 1).
Diffraction data were collected on an Oxford Diffraction
Gemini four-circle system with a Ruby CCD area detector. The
structure was refined by full-matrix least squares against F2
using SHELXL 97 and solved by direct methods using SHELXS
(TREF) with additional light atoms found by Fourier
methods.55 Hydrogen atoms were added at calculated posi-
tions and refined using a riding model. Anisotropic displace-
ment parameters were used for all non-H atoms; H-atoms were
given an isotropic displacement parameter equal to 1.2 (or 1.5
for methyl and NH H-atoms) times the equivalent isotropic
displacement parameter of the atom to which they are
attached. The data were processed by the modelling program
Mercury 1.4.1. X-ray crystallographic data for complex 1 have
been deposited in the Cambridge Crystallographic Data Centre
under the accession number CCDC 2067332.†
Mass spectrometry
Electrospray mass spectra were obtained using a Bruker MaXis
UHR-ESI-TOF instrument. Samples of 1 and [187Os]-1 were pre-
pared in methanol and analysed in positive ion mode
(500–1000 m/z).
NMR spectroscopy
1H and 13C NMR spectra were acquired in 5 mm NMR tubes at
298 K on Bruker AV-250, AV-400, AV-600 or AV-700 spec-
trometers in MeCN-d3. Data processing was carried out using
TOPSPIN version 2.1 (Bruker UK Ltd). 1H NMR chemical shifts
were internally referenced to TMS via the residual solvent
Dalton Transactions Paper

























































































peak: acetonitrile (δ = 1.94 ppm).56 Likewise for 13C NMR
chemical shifts: acetonitrile (δ = 1.32 ppm). 1D 1H NMR
spectra were recorded using standard pulse sequences and 1D
13C NMR spectra were recorded using a J-MOD pulse sequence.
Typically, 1H data were acquired with 16 transients into 32k
data points over a spectral width of 14 ppm, and 13C data with
8192 transients into 64k data points over a spectral width of
220 ppm.
1H–187Os HMBC NMR spectroscopy was carried out with
MeCN-d3 as solvent at 298 K on an Advance III 600 (
1H =
600.13 MHz, 187Os = 13.69 MHz) spectrometer equipped with a
5 mm triple resonance broadband inverse (TBI-Lr) 1H/31P/BB
probe with z-field gradients. The 90° pulse length for 187Os
was 11 μs. The 187Os resonance frequency was roughly esti-
mated from a series of 1H–187Os HMBC experiments carried
out with incremented values of the carrier frequency. In order
to check for the absence of folding in the F1 dimension, two
gradient-enhanced HMBC spectra were recorded with different
settings of the 187Os spectral width and offset (SW = 1000 ppm
O1P = −3800 and −4500 respectively). The second, shown in
Fig. 7, was recorded with the following experimental con-
ditions: 128 transients collected for each FID, 32 increments,
1/2J delay set to 0.1 s, recycling delay 2.25 s; three sine-shaped
gradients pulses of 1 ms duration in the intensity ratio of
60 : 20 : 41.83 for coherence (echo type) selection; sine bell
multiplication in both dimensions and zero filling to 1024
data points in the F1 dimension was applied before Fourier
transform followed by magnitude calculation. The reference
frequency for the 187Os chemical shift was calculated from the
proton frequency of internal TMS, using a conversion factor Ξ
= 2.282331.
187Os NMR spectroscopy was carried out using MeCN-d3 as
solventat 298 K on an Avance III 600 (1H = 600.13 MHz, 187Os =
13.69 MHz) spectrometer equipped with a 5 mm triple reso-
nance broadband inverse (TBI-Lr) 1H/31P/BB probe with z-field
gradients. The 90° pulse length for osmium was 11 μs. A series
of experiments was carried out with incremented values of the
carrier frequency in order to scan the full 10 000 ppm scale
(SW = 1000 ppm O1P = from 4500 to −4500). A standard 1D
sequence with power gated decoupling was used with 256
scans, recycling delay 4 s.
Cytotoxicity assay
A stock solution of 1 was prepared in cell culture medium (5%
DMSO). Approximately 5000 A2780 human ovarian cancer cells
were seeded per well in 96-well plates. The cells were pre-incu-
bated in drug-free media at 37 °C for 48 h before adding
different concentrations of 1. Cells were exposed to 1 for 24 h
at 37 °C and then allowed to recover for 72 h in a drug-free
medium at 37 °C. Then the supernatants were removed by
suction and the cells washed with PBS. The cells were The SRB
assay was used to determine cell viability. Absorbance
measurements of the solubilised dye (on a BioRad iMark
microplate reader using a 470 nm filter) allowed the determi-
nation of viable treated cells compared to untreated controls.
IC50 values (the concentration at which 50% cell death occurs)
were determined as triplicates of duplicates for each complex.
ICP-OES (PerkinElmer Optima 5300 DV instrument) was used
to determine [Os] of the stock solution of 1, and the IC50 value
was corrected for ICP factor.
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